HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease
18 juil. 2024 09h00 HE
|
HeartFlow Holding, Inc.
Technology offers benefits of HeartFlow Plaque Analysis with the new addition of 3D interactive capabilities, integrated with lesion specific FFRCT values WASHINGTON, July 18, 2024 (GLOBE...
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
03 juin 2024 12h00 HE
|
HeartFlow Holding, Inc.
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
HeartFlow Announces Publication of 10-year Follow-Up Data from the DISCOVER-FLOW Study in the Journal of Cardiovascular Computed Tomography
12 mars 2024 09h00 HE
|
HeartFlow Holding, Inc.
HeartFlow's non-invasive AI driven FFRCT predicts patient outcomes as effectively as the gold-standard invasive FFR out to 10 years MOUNTAIN VIEW, Calif., March 12, 2024 (GLOBE NEWSWIRE) --...
HeartFlow Announces New Reimbursement Code and Increased Payment for FFRCT
23 janv. 2024 09h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary solutions, announced FFRCT was transitioned to a...
HeartFlow, Leader in Revolutionizing Precision Heart Care, Closes $215 Million in Series F Funding Led by Bain Capital Life Sciences
06 avr. 2023 07h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced the close of a $215 million Series F funding round by...
CORRECTION -- Late-breaking Data Demonstrate AHA/ACC Guideline-directed CCTA ± FFRCT Precision Pathway is Superior to Traditional Testing
06 nov. 2022 20h20 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., Nov. 06, 2022 (GLOBE NEWSWIRE) -- Please note the link in the second paragraph has been updated from the original release issued under the same headline earlier today by...
Late-breaking Data Demonstrate AHA/ACC Guideline-directed CCTA ± FFRCT Precision Pathway is Superior to Traditional Testing
06 nov. 2022 19h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., Nov. 06, 2022 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in revolutionizing precision heartcare, today announced new trial results that show evaluating patients with...
HeartFlow Receives FDA 510(k) Clearance for its Plaque Analysis and RoadMap™ Analysis
18 oct. 2022 10h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in revolutionizing precision heart care, has received U.S. Food and Drug Administration (FDA) 510(k) clearance on...
Presented at SCCT - New Plaque Clinical Data Provides Additional Insights on Anatomy and Physiology in Clinical Decision Making for Patients
21 juil. 2022 11h00 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- HeartFlow, Inc., the leader in revolutionizing precision heart care, released two datasets utilizing its HeartFlow AI-based Plaque...